Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 7/20 | 0.57 |
| ▸ | RAB9A | P51151 | 4/20 | 0.57 |
| ▸ | KDM4E | B2RXH2 | 7/20 | 0.57 |
| ▸ | LMNA | P02545 | 6/20 | 0.57 |
| ▸ | NPC1 | O15118 | 3/20 | 0.57 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.57 |
| ▸ | MEN1 | O00255 | 2/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.57 |
| ▸ | GAA | P10253 | 2/20 | 0.57 |
| ▸ | POLB | P06746 | 2/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.53 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.53 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.52 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.52 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.52 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.52 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.52 |
| ▸ | HPGD | P15428 | 2/20 | 0.52 |
| ▸ | HTT | P42858 | 1/20 | 0.52 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1651611 | 0.84 | MAPT (0.60) | MAPTRAB9AKDM4ELMNANPC1 | |
| SCHEMBL2484526 | 0.82 | MAPT (0.66) | MAPTRAB9AKDM4ELMNANPC1 | |
| SCHEMBL2484185 | 0.81 | MAPT (0.68) | MAPTRAB9AKDM4ELMNANPC1 | |
| SCHEMBL1100857 | 0.80 | MAPT (0.62) | MAPTRAB9AKDM4ELMNANPC1 | |
| SCHEMBL9568616 | 0.80 | MAPT (0.66) | MAPTRAB9AKDM4ELMNANPC1 | |
| SCHEMBL5807624 | 0.79 | LMNA (0.69) | MAPTRAB9AKDM4ELMNANPC1 | |
| SCHEMBL1101347 | 0.79 | MAPT (0.68) | MAPTRAB9AKDM4ELMNANPC1 | |
| SCHEMBL9632939 | 0.78 | MCHR1 (0.67) | MAPTRAB9AKDM4ELMNANPC1 | |
| SCHEMBL18691791 | 0.78 | MCHR1 (0.67) | MAPTRAB9AKDM4ELMNANPC1 | |
| SCHEMBL16114005 | 0.78 | MCHR1 (0.67) | MAPTRAB9AKDM4ELMNANPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7718621-B2 | Macrolones—amino substituted quinolones | GLAXO GROUP LTD. (GB) | 2010-05-18 | — | — | US | disclosed |
| US-20090111760-A1 | MACROLONE COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2009-04-30 | — | — | US | disclosed |
| US-20090062218-A1 | MACROLONE COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2009-03-05 | — | — | US | disclosed |
| US-20080096829-A1 | Macrolone Compounds | GLAXO GROUP LIMITED (GB) | 2008-04-24 | — | — | US | disclosed |
| US-20080090773-A1 | Macrolones - Amino Substituted Quinolones | GLAXO GROUP LIMITED (GB) | 2008-04-17 | — | — | US | disclosed |
| EP-1824497-A1 | MACROLONE COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2007-08-29 | — | — | EP | disclosed |
| EP-1824870-A1 | MACROLONES - AMINO SUBSTITUTED QUINOLONES | GLAXO GROUP LIMITED (GB) | 2007-08-29 | — | — | EP | disclosed |
| EP-1824869-A1 | MACROLONE COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2007-08-29 | — | — | EP | disclosed |
| EP-1824871-A1 | MACROLONE COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2007-08-29 | — | — | EP | disclosed |
| WO-2006050940-A1 | MACROLONE COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2006-05-18 | — | — | WO | disclosed |
| WO-2006050942-A1 | MACROLONES - AMINO SUBSTITUTED QUINOLONES | GLAXO GROUP LIMITED (GB) | 2006-05-18 | — | — | WO | disclosed |
| WO-2006050941-A1 | MACROLONE COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2006-05-18 | — | — | WO | disclosed |
| WO-2006050943-A1 | MACROLONE COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2006-05-18 | — | — | WO | disclosed |
| WO-2000009131-A1 | DIAMINOPYRIMIDINES AND COMBINATION THERAPIES EFFECTIVE FOR TREATMENT OF P-GLYCOPROTEIN POSITIVE CANCERS | WARNER-LAMBERT COMPANY (US) | 2000-02-24 | — | — | WO | disclosed |
| US-4735943-A | VASODILATORS | SANWA KAGAKU KENKYUSHO CO., LTD. (JP) | 1988-04-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090111760-A1 | MACROLONE COMPOUNDS | CYP51A1, MRPL21, MYD88 | MAPT 3397/4885RAB9A 2580/4885KDM4E 3897/4885 |
| US-20090062218-A1 | MACROLONE COMPOUNDS | CYP51A1, MRPL21, MYD88 | MAPT 3397/4885RAB9A 2580/4885KDM4E 3897/4885 |
| US-20080090773-A1 | Macrolones - Amino Substituted Quinolones | MRPL21, Q6ZSR9, QARS1 | MAPT 3434/4885RAB9A 696/4885KDM4E 2889/4885 |
| US-20080096829-A1 | Macrolone Compounds | MRPL21, MRPS18A, MRPL19 | MAPT 3953/4885RAB9A 2463/4885KDM4E 4136/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.